Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.
Thirty-seven per cent of patients in a closely watched clinical...